Efficacy and safety of Yttrium 90 (90Y) ibritumomab tiuxetan in autologous and nonmyeloablative stem cell transplantation (NST) for relapsed non-Hodgkin's lymphoma (NHL).

被引：7

作者：

Khouri, Issa F. ^{[1
]}

Saliba, Rima M. ^{[1
]}

Hosing, Chitra ^{[1
]}

Valverde, Rosamar ^{[1
]}

Erwin, William D. ^{[1
]}

Fayad, Luis ^{[1
]}

Maadani, Farzaneh ^{[1
]}

Korbling, Martin J. ^{[1
]}

Okoroji, Grace-Julia ^{[1
]}

Stachowiak, Anne M. ^{[1
]}

Samuels, Barry I. ^{[1
]}

Anderlini, Paolo ^{[1
]}

Couriel, Daniel R. ^{[1
]}

de Lima, Marcos ^{[1
]}

Giralt, Sergio ^{[1
]}

Popat, Uday ^{[1
]}

Kebriaei, Partow ^{[1
]}

Ueno, Naoto T. ^{[1
]}

Qazilbash, Muzaffar H. ^{[1
]}

McLaughlin, Peter W. ^{[1
]}

Hagemeister, Fredrick B. ^{[1
]}

Younes, Anas ^{[1
]}

Podoloff, Donald A. ^{[1
]}

Champlin, Richard E. ^{[1
]}

机构：

[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

BLOOD | 2006年 / 108卷 / 11期

关键词：

D O I：

10.1182/blood.V108.11.315.315

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

315

引用

页码：98A / 98A

页数：1

共 50 条

[11] Efficacy and safety of yttrium-90 ibritumomab tiuxetan in the treatment of non-Hodgkin lymphoma
Doyle, Catherine
Smith, Johnna
Bello, Celeste M.
Sokol, Lubomir
El-Haddad, Ghassan
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (05)
[12] Cellular localization pattern of yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin®) in a patient with low-grade non-Hodgkin's lymphoma (NHL).
Jacobs, SA
Harrison, AM
Swerdlow, SH
Foon, KA
Avril, N
Vidnovic, N
McCarty, KS
Saville, W
BLOOD, 2004, 104 (11) : 226B - 226B
[13] Dose finding trial of Yttrium 90 ibritumomab tiuxetan (90YIT) with autologous stem cell transplantation (ASCT) in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL).
Flinn, I. W.
Kahl, B. S.
Frey, E. C.
Bianco, J. A.
Hammes, R. J.
Webb, J.
Swinnen, L. J.
Sgouros, G.
Wahl, R. L.
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 430S - 430S
[14] Safety and efficacy of yttrium-90 ibritumomab tiuxetan in older patients with non-hodgkin's lymphoma
Emmanouilides, Christos
Witzig, Thomas E.
Wiseman, Gregory A.
Gordon, Leo I.
Wang, Hua
Schilder, Russell
Saville, M. Wayne
Flinn, Ian
Molina, Arturo
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2007, 22 (05) : 684 - 691
[15] Radioimmunotherapy with 90Y Ibritumomab Tiuxetan in patients with relapsed or refractory B-cell non-Hodgkin lymphoma
Olivas, C.
Bello, P.
Vercher, J. L.
Loaiza, J. L.
Marti, J. F.
Hervas, I.
Rivas, A.
Ruiz, C.
Perez-Velasco, R.
Mateo, A.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2009, 36 : S419 - S419
[16] 90Y ibritumomab tiuxetan for consolidation after autologous stem cell trasplantation in high-grade non-Hodgkin lymphoma
Ria, R.
Musto, P.
Barletta, M. A.
Guariglia, R.
Iodice, G.
Vacca, A.
Dammacco, F.
BONE MARROW TRANSPLANTATION, 2008, 41 : S422 - S423
[17] Efficacy and safety of yttrium-90 ibritumomab tiuxetan in Japanese patients with non-Hodgkin lymphoma
Nakagawa, Makoto
Uike, Naokuni
Choi, Ilseung
Hayashi, Toshinobu
Uehara, Satoru
JAPANESE JOURNAL OF RADIOLOGY, 2012, 30 (08) : 642 - 647
[18] Efficacy and safety of yttrium-90 ibritumomab tiuxetan in Japanese patients with non-Hodgkin lymphoma
Makoto Nakagawa
Naokuni Uike
Ilseung Choi
Toshinobu Hayashi
Satoru Uehara
Japanese Journal of Radiology, 2012, 30 : 642 - 647
[19] Analysis of relationship between baseline body weight and efficacy/safety of yttrium 90 (90Y) ibritumomab tiuxetan radioimmunotherapy in patients (pts) with non-Hodgkin's lymphoma
Wiseman, GA
Emmanouilides, C
Vo, K
Schilder, RJ
Foster, P
Gordon, LI
Witzig, TE
Molina, A
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 607S - 607S
[20] Evaluation of baseline body-weight dosing of yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin®) radioimmunotherapy in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL).
Wiseman, G
Conti, P
Vo, K
Schilder, RJ
Foster, P
Gordon, LI
Emmanouilides, C
Silverman, D
Witzig, TE
Molina, A
BLOOD, 2004, 104 (11) : 721A - 721A

← 1 2 3 4 5 →